{"id":31747,"date":"2025-04-15T11:42:44","date_gmt":"2025-04-15T03:42:44","guid":{"rendered":"https:\/\/flcube.com\/?page_id=31747"},"modified":"2025-04-15T11:42:44","modified_gmt":"2025-04-15T03:42:44","slug":"mar-2025-fineline-deals-book","status":"publish","type":"page","link":"https:\/\/flcube.com\/?page_id=31747","title":{"rendered":"Mar. 2025 Fineline Deals Book"},"content":{"rendered":"\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>China Pharmaceutical BD Transaction Review &#8211; Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. &#8211; Fineline Deals Book Mar. 2025<\/p>\n<\/blockquote>\n\n\n\n<p class=\"is-style-info\">According to incomplete statistics from Fineline Info &amp; Tech, there were a total of <strong>21<\/strong> pharmaceutical BD and M&amp;A transactions in China in Mar 2025, including <strong>3<\/strong> cross-border asset acquisitions, <strong>7<\/strong> outbound transactions, and <strong>11<\/strong> domestic transactions.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"193\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" src=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-1024x193.png\" alt=\"Fineline Info &amp; Tech\" class=\"wp-image-13755\" srcset=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-1024x193.png 1024w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-300x57.png 300w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-768x145.png 768w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-610x115.png 610w, https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png 1214w\" \/><\/figure>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/Mar.-2025-Fineline-Deals-Book-3.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Mar. 2025 Fineline Deals Book.\"><\/object><a id=\"wp-block-file--media-6856a7f0-cc76-4207-8a8a-e2cff43d8776\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/Mar.-2025-Fineline-Deals-Book-3.pdf\">Mar. 2025 Fineline Deals Book<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/Mar.-2025-Fineline-Deals-Book-3.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6856a7f0-cc76-4207-8a8a-e2cff43d8776\">Download<\/a><\/div>\n\n\n\n<div class=\"wp-block-coblocks-features coblocks-features-115104548427\"><div class=\"wp-block-coblocks-features__inner has-1-columns has-left-content has-no-gutter\">\n\n<div class=\"wp-block-coblocks-feature coblocks-feature-115104548517\"><div class=\"wp-block-coblocks-feature__inner has-no-padding\">\n\n\n<h4 class=\"wp-block-heading\" id=\"h-cross-border-license-in\">Cross-border License In<\/h4>\n\n<\/div><\/div>\n\n<\/div><\/div>\n\n\n\n<p class=\"has-text-align-left\"><a href=\"https:\/\/flcube.com\/?p=28814\"><strong>Yifan Pharma Secures Rights to Bayer\u2019s Stivarga and Nexavar in China<\/strong><\/a><\/p>\n\n\n\n<p>China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a commercialization agreement with Bayer (ETR: BAYN),&#8230; [<a href=\"https:\/\/flcube.com\/?p=28814\">Full Artical<\/a>]<\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong><a href=\"https:\/\/flcube.com\/?p=28320\"><a href=\"https:\/\/flcube.com\/?p=29083\">WuXi XDC and AbTis Partner to Advance Antibody-Drug Conjugate Innovation<\/a><\/a><\/strong><\/p>\n\n\n\n<p>WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA&#8230; [<a href=\"https:\/\/flcube.com\/?p=29083\">Full Artical<\/a>]<\/p>\n\n\n\n<p class=\"has-text-align-left\"><strong><a href=\"https:\/\/flcube.com\/?p=28320\"><a href=\"https:\/\/flcube.com\/?p=30893\">Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma<\/a><\/a><\/strong><\/p>\n\n\n\n<p>Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton&#8230; [<a href=\"https:\/\/flcube.com\/?p=30893\">Full Artical<\/a>]<\/p>\n\n\n\n<div class=\"wp-block-coblocks-features coblocks-features-115104548427\"><div class=\"wp-block-coblocks-features__inner has-1-columns has-left-content has-no-gutter\">\n\n<div class=\"wp-block-coblocks-feature coblocks-feature-115104548517\"><div class=\"wp-block-coblocks-feature__inner has-no-padding\">\n\n\n<h4 class=\"wp-block-heading\" id=\"h-cross-border-license-out\">Cross-border License Out<\/h4>\n\n<\/div><\/div>\n\n<\/div><\/div>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=20433\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=25864\"><\/a><a href=\"https:\/\/flcube.com\/?p=29236\"><\/a><a href=\"https:\/\/flcube.com\/?p=30158\">Harbour BioMed Partners with AstraZeneca on Multi-Specific Antibody Development<\/a><\/strong><\/p>\n\n\n\n<p>China-based Harbour BioMed (HKG: 2142) has formed a strategic partnership with UK pharmaceutical giant AstraZeneca&#8230; [<a href=\"https:\/\/flcube.com\/?p=30158\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=20440\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=29236\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=29236\"><\/a><a href=\"https:\/\/flcube.com\/?p=30175\">Syneron Bio Collaborates with AstraZeneca to Develop Macrocyclic Peptides for Chronic Diseases<\/a><\/strong><\/strong><\/p>\n\n\n\n<p>China-based Syneron Bio, a biotech firm specializing in macrocyclic peptide drugs, has entered into a&#8230;[<a href=\"https:\/\/flcube.com\/?p=30175\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=28361\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=27257\"><\/a><a href=\"https:\/\/flcube.com\/?p=30395\">United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug<\/a><\/strong><\/p>\n\n\n\n<p>Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement&#8230;[<a href=\"https:\/\/flcube.com\/?p=30395\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21218\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=27250\"><\/a><a href=\"https:\/\/flcube.com\/?p=30706\">Bayer Inks Licensing Deal for Suzhou Puhe\u2019s PRMT5 Inhibitor, BAY 3713372<\/a><\/strong><\/p>\n\n\n\n<p>German pharmaceutical giant Bayer (ETR: BAYN) has entered into a licensing agreement with Suzhou Puhe&#8230; [<a href=\"https:\/\/flcube.com\/?p=30706\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21064\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=27333\"><\/a><a href=\"https:\/\/flcube.com\/?p=30730\">Bio-Thera Solutions Inks Licensing Deal with Dr. Reddy\u2019s for Biosimilar Commercialization<\/a><\/strong><\/p>\n\n\n\n<p>Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a licensing agreement with India-headquartered Dr. Reddy\u2019s&#8230;[<a href=\"https:\/\/flcube.com\/?p=30730\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=28338\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=27567\"><\/a><a href=\"https:\/\/flcube.com\/?p=31759\">Bioray Biopharmaceutical Expands to Turkey with Three Key Drugs, Marking International Milestone<\/a><\/strong><\/p>\n\n\n\n<p>Zhejiang Bioray Biopharmaceutical Co., Ltd. announced on March 31 that it has reached a collaboration&#8230;[<a href=\"https:\/\/flcube.com\/?p=31759\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=28371\"><\/a><\/p>\n\n\n\n<div class=\"wp-block-coblocks-features coblocks-features-115104548427\"><div class=\"wp-block-coblocks-features__inner has-1-columns has-left-content has-no-gutter\">\n\n<div class=\"wp-block-coblocks-feature coblocks-feature-115104548517\"><div class=\"wp-block-coblocks-feature__inner has-no-padding\">\n\n\n<h4 class=\"wp-block-heading\" id=\"h-domestic-transactions-in-china\">Domestic Transactions in China<\/h4>\n\n<\/div><\/div>\n\n<\/div><\/div>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=20562\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=28791\"><\/a><a href=\"https:\/\/flcube.com\/?p=28771\"><a href=\"https:\/\/flcube.com\/?p=28771\">Insilico Medicine and Tenacia Partner on AI-Driven CNS Therapies<\/a><\/a><\/strong><\/p>\n\n\n\n<p>China\u2019s generative artificial intelligence (AI)-driven biotech Insilico Medicine has formed a partnership with compatriot firm&#8230; [<a href=\"https:\/\/flcube.com\/?p=28771\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=28345\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=29304\"><\/a><a href=\"https:\/\/flcube.com\/?p=28830\"><a href=\"https:\/\/flcube.com\/?p=28830\">Jiangsu Nhwa Pharmaceutical Invests in NeuroThree to Develop CNS Therapies<\/a><\/a><\/strong><\/p>\n\n\n\n<p>China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced plans to subscribe to Hong Kong-headquartered&#8230; [<a href=\"https:\/\/flcube.com\/?p=28830\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21475\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=27724\"><\/a><a href=\"https:\/\/flcube.com\/?p=28922\"><a href=\"https:\/\/flcube.com\/?p=28922\">Sino Biopharmaceutical Licenses Nanjing Delova\u2019s QP001 for Mainland China Rights<\/a><\/a><\/strong><\/p>\n\n\n\n<p>China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced acquiring exclusive rights to Nanjing Delova Biotech Co.,Ltd\u2019s&#8230;[<a href=\"https:\/\/flcube.com\/?p=28922\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21789\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=28314\"><\/a><a href=\"https:\/\/flcube.com\/?p=31768\">Anlong Biopharmaceutical and Sun-Novo Partner to Advance siRNA Technology in Cardiovascular Treatments<\/a><\/strong><\/p>\n\n\n\n<p>On March 10, 2025, Anlong Biopharmaceutical and Sun-Novo Pharmaceutical announced a strategic partnership to advance&#8230; [<a href=\"https:\/\/flcube.com\/?p=31768\">Full Artical<\/a>]<\/p>\n\n\n\n<p><strong><a href=\"https:\/\/flcube.com\/?p=29126\">Newdel Biotech Secures A+ Round Funding to Accelerate DEL+AI-Driven Drug Discovery<\/a><\/strong><\/p>\n\n\n\n<p>Newdel Biotech recently announced the completion of an A+ round strategic investment led by XtalPi&#8230;[<a href=\"https:\/\/flcube.com\/?p=29126\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21789\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=28314\"><\/a><a href=\"https:\/\/flcube.com\/?p=31774\">Convalife and XLement Launch AI-Powered Joint Lab for Drug Development Innovation<\/a><\/strong><\/p>\n\n\n\n<p>On March 19, 2025, Convalife Pharmaceuticals and XLement announced a strategic partnership to establish the&#8230; [<a href=\"https:\/\/flcube.com\/?p=31774\">Full Artical<\/a>]<\/p>\n\n\n\n<p><strong><a href=\"https:\/\/flcube.com\/?p=30250\">CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China<\/a><\/strong><\/p>\n\n\n\n<p>Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an&#8230;[<a href=\"https:\/\/flcube.com\/?p=30250\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21789\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=28314\"><\/a><a href=\"https:\/\/flcube.com\/?p=30234\">Kexing Biopharm Partners with BioMap on AI-Driven Macromolecular Drug Development<\/a><\/strong><\/p>\n\n\n\n<p>China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with US biotech firm BioMap&#8230; [<a href=\"https:\/\/flcube.com\/?p=30234\">Full Artical<\/a>]<\/p>\n\n\n\n<p><strong><a href=\"https:\/\/flcube.com\/?p=30693\">Shanghai RAAS Plans RMB4.2 Billion Acquisition of Nanyue BioPharming to Boost Plasma Resources<\/a><\/strong><\/p>\n\n\n\n<p>China\u2019s Shanghai RAAS (SHE: 002252) has announced plans to acquire 100% stakes in compatriot firm&#8230;[<a href=\"https:\/\/flcube.com\/?p=30693\">Full Artical<\/a>]<\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?p=21789\"><\/a><strong><a href=\"https:\/\/flcube.com\/?p=28314\"><\/a><a href=\"https:\/\/flcube.com\/?p=30711\">Insilico Medicine Collaborates with Mabwell Bio to Enhance ADC R&amp;D with AI<\/a><\/strong><\/p>\n\n\n\n<p>China\u2019s generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into a collaboration with compatriot&#8230; [<a href=\"https:\/\/flcube.com\/?p=30711\">Full Artical<\/a>]<\/p>\n\n\n\n<p><strong><a href=\"https:\/\/flcube.com\/?p=31783\">Apollomics Partners with LaunXP for Vebreltinib in Asian NSCLC Treatment<\/a><\/strong><\/p>\n\n\n\n<p>Apollomics Inc. announced on March 31, 2025, a strategic development and commercialization agreement with Taiwan-based&#8230;[<a href=\"https:\/\/flcube.com\/?p=31783\">Full Artical<\/a>]<\/p>\n\n\n\n<p><em>For more insights, follow <a href=\"https:\/\/flcube.com\">Fineline Info &amp; Tech<\/a><\/em><\/p>\n\n\n\n<p><strong>Previous Recommendations<\/strong><a href=\"https:\/\/flcube.com\/?page_id=21585\"><\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?page_id=29292\">Feb. 2025 Fineline Deals Book<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?page_id=28350\">Jan. 2025 Fineline Deals Book<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?page_id=21585\">Dec. 2024 Fineline Deals Book<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/flcube.com\/?page_id=16824\">Nov. 2024 Fineline Deals Book<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China Pharmaceutical BD Transaction Review &#8211; Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","footnotes":""},"class_list":["post-31747","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mar. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book Mar. 2025\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?page_id=31747\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mar. 2025 Fineline Deals Book\" \/>\n<meta property=\"og:description\" content=\"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book Mar. 2025\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?page_id=31747\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1214\" \/>\n\t<meta property=\"og:image:height\" content=\"229\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=31747\",\"url\":\"https:\\\/\\\/flcube.com\\\/?page_id=31747\",\"name\":\"Mar. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=31747#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=31747#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/38-02-1024x193.png\",\"datePublished\":\"2025-04-15T03:42:44+00:00\",\"description\":\"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book Mar. 2025\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=31747#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?page_id=31747\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=31747#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/38-02.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/38-02.png\",\"width\":1214,\"height\":229,\"caption\":\"Fineline Info & Tech\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?page_id=31747#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mar. 2025 Fineline Deals Book\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mar. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry","description":"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book Mar. 2025","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?page_id=31747","og_locale":"en_US","og_type":"article","og_title":"Mar. 2025 Fineline Deals Book","og_description":"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book Mar. 2025","og_url":"https:\/\/flcube.com\/?page_id=31747","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","og_image":[{"width":1214,"height":229,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/flcube.com\/?page_id=31747","url":"https:\/\/flcube.com\/?page_id=31747","name":"Mar. 2025 Fineline Deals Book - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?page_id=31747#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?page_id=31747#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02-1024x193.png","datePublished":"2025-04-15T03:42:44+00:00","description":"China Pharmaceutical BD Transaction Review - Deeply empowering pharmaceutical transactions to facilitate collaboration and jointly build a new ecosystem for BD communication. - Fineline Deals Book Mar. 2025","breadcrumb":{"@id":"https:\/\/flcube.com\/?page_id=31747#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?page_id=31747"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?page_id=31747#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/38-02.png","width":1214,"height":229,"caption":"Fineline Info & Tech"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?page_id=31747#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mar. 2025 Fineline Deals Book"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages\/31747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31747"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages\/31747\/revisions"}],"predecessor-version":[{"id":31790,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/pages\/31747\/revisions\/31790"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}